LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Patients taking Novo Nordisk’s anti-obesity jab sustained weight loss for up to four years and had a ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday.
(Updates shares in paragraph 6, side effects in paragraph 12) By Maggie Fick LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight ...